Drug Trial Radar · NCT05657301
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Oct 16, 2023
Primary completion
Sep 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid. A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular intraocular injections.
Conditions
- Age-Related Macular Degeneration
Interventions
KH631Drug
KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety (Type, Severity and Incidence of ocular and systemic AEs and SAEs)Time frame: 52 Weeks
- Best Corrected Visual AcuityTime frame: 52 Weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Kanghong Investigative Site
Phoenix, Arizona
Kanghong Investigative Site
Lemont, Illinois
Kanghong Investigative Site
Boston, Massachusetts
Kanghong Investigative Site
Reno, Nevada
Kanghong Investigative Site
Cherry Hill, New Jersey
Kanghong Investigative Site
Germantown, Tennessee
Kanghong Investigative Site
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.